Steven D. Singer has more than three decades of experience as a corporate attorney who has represented clients in a wide range of transactions. He has advised numerous public and private companies in the life sciences industry, focusing on joint ventures and strategic alliances, corporate and securities law, public offerings and venture capital transactions.
Mr. Singer is consistently recognized in the areas of corporate and life sciences for successfully handling complex deals and collaborations in the technology transactions and licensing sector.
Mr. Singer has focused his practice in the life sciences industry for more than three decades. He has served as counsel for public and private companies in the life sciences sector, including biotechnology, medical device and pharmaceutical companies. His practice focuses on joint ventures and strategic alliances, corporate and securities laws, public offerings and venture capital transactions.
Mr. Singer has worked with the following public company clients, among others: Achillion, Agios, Aveo, Catabasis, Cerulean, Curis, Editas, Infinity, Karyopharm and Syros. Representative private company clients include Constellation, Cydan, Decibel, Fulcrum, Visterra and X-Chem. Mr. Singer has also worked with pharmaceutical companies, including Bristol Myers Squibb, Novartis and Wyeth.
Mr. Singer has also worked with New York-based medical and academic institutions in the establishment and operation of an independent, nonprofit genome sequencing center, the Tri-Institutional Therapeutics Discovery Institute and Bridge Medicines.
Mr. Singer serves on the Boards of Directors of the New York Genome Center and The Possible Project. Mr. Singer is a member of the American Bar Association, the Biotechnology Industry Organization and the Massachusetts Biotechnology Council.
- Over the last several years, representation of the following companies in their initial public offerings and follow-on offerings: Agios, Catabasis, Cerulean, Constellation, Editas, Kala, Karyopharm and Syros
- Representation of New York-based academic and medical institutions in the establishment of research and development vehicles—Tri-I Therapeutics Discovery Institute and Bridge Medicines
- Representation of MacroGenics in its alliances with Janssen, Servier, Takeda and Incyte
- Representation of an independent, nonprofit genome sequencing center and consortium in its organization as a 501(c)(3) organization with multiple medical and academic institutions as members
- Representation of Voyager Therapeutics in its collaboration with Neurocrine Biosciences
- Representation of Decibel in its collaboration with Regeneron.
- JD, Harvard Law School, 1979
- BA, Tufts University, 1976
ADMISSIONS : New York, Massachusetts
Rate : $$$